| scholarly article | Q13442814 |
| P50 | author | John M. Kane | Q52274733 |
| Christoph Correll | Q56954221 | ||
| P2093 | author name string | Martha Sajatovic | |
| Ruth Ross | |||
| Faith DiBiasi | |||
| Heather Fitzgerald | |||
| Matthew Byerly | |||
| Susan N Legacy | |||
| P2860 | cites work | Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia | Q24597701 |
| Practice guideline for the treatment of patients with schizophrenia, second edition. | Q33976372 | ||
| Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder | Q34267385 | ||
| Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry | Q34357174 | ||
| The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. | Q34418847 | ||
| Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses | Q34588656 | ||
| Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature | Q34989186 | ||
| Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies | Q35042829 | ||
| Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness | Q35073474 | ||
| Clinical predictors of therapeutic response to antipsychotics in schizophrenia | Q35109168 | ||
| Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory | Q35211261 | ||
| The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. | Q35593695 | ||
| A Systemic Review and Experts' Consensus for Long-acting Injectable Antipsychotics in Bipolar Disorder | Q35965634 | ||
| Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia. | Q50561566 | ||
| Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. | Q51859244 | ||
| Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. | Q53023011 | ||
| Guidelines for the use of second-generation long-acting antipsychotics | Q62590125 | ||
| A method for the detailed assessment of the appropriateness of medical technologies | Q77661056 | ||
| Attitudes of psychiatrists toward antipsychotic depot medication | Q79459271 | ||
| Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral | Q85480808 | ||
| Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies | Q88989907 | ||
| Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians' perceptions of adherence vs. pharmacy claims | Q36371461 | ||
| Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia | Q36597061 | ||
| The case for long-acting antipsychotic agents in the post-CATIE era. | Q36758680 | ||
| Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a Roadmap. | Q36890580 | ||
| Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies | Q37236148 | ||
| Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial | Q37341552 | ||
| Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). | Q37386164 | ||
| Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials | Q37451403 | ||
| Clinical guideline recommendations for antipsychotic long-acting injections | Q37625696 | ||
| History and therapeutic rationale of long acting antipsychotics | Q38076207 | ||
| Determinants of adherence to treatment in bipolar disorder: a comprehensive review | Q38089269 | ||
| Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective | Q38115487 | ||
| Ambiguous findings concerning potential advantages of depot antipsychotics: in search of clinical relevance | Q38382731 | ||
| A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia | Q38397554 | ||
| Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia. | Q38851847 | ||
| Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients: A Systematic Review | Q38852539 | ||
| The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence | Q38978919 | ||
| The challenge of offering long-acting antipsychotic therapies: a preliminary discourse analysis of psychiatrist recommendations for injectable therapy to patients with schizophrenia | Q40979367 | ||
| Attitudes toward antipsychotic treatment among patients with bipolar disorders and their clinicians: a systematic review | Q41633896 | ||
| Consensus methods in practice guideline development: a review and description of a new method. | Q41716882 | ||
| Antipsychotic long-acting injections: prescribing practice in the UK. | Q43251056 | ||
| Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. | Q44142664 | ||
| Psychiatrists' use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years | Q46440782 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1463-1474 | |
| P577 | publication date | 2018-06-08 | |
| P1433 | published in | Neuropsychiatric Disease and Treatment | Q15716332 |
| P1476 | title | Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics - expert consensus survey part 1. | |
| P478 | volume | 14 |
| Q98289116 | The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review | cites work | P2860 |
Search more.